A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2-negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: A study protocol

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Kümler, Iben ^a   Balslev, Eva ^a   Stenvang, Jan ^b   Brünner, Nils ^b   Nielsen, Dorte ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE; IRINOTECAN; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; GENETIC MARKER; TOP1 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; DENMARK; DIARRHEA; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOXICITY; DRUG WITHDRAWAL; GENE DOSAGE; GENE OVEREXPRESSION; HUMAN; HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE BREAST CANCER; HUMAN TISSUE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TOP1 GENE; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; GENETIC MARKER; GENETICS; METASTASIS; PATHOLOGY; TREATMENT OUTCOME;

BREAST NEOPLASMS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE DOSAGE; GENETIC MARKERS; HUMANS; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; TOPOISOMERASE I INHIBITORS; TREATMENT OUTCOME;

EID: 84928668068     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1072-9     Document Type: Article

References (38)

1. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100(16):1179-83.
2. Nielsen D, Dombernowsky P, Larsen SK, Hansen OP, Skovsgaard T. Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemother Pharmacol. 2000;46(6):459-66.
3. Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR, et al. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol. 1991;9(12):2148-52.
4. Fountzilas G, Athanassiades A, Giannakakis T, Briasoulis E, Bafaloukos D, Kalogera-Fountzila A, et al. A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol. 1997;8(12):1213-20.
5. Michelotti A, Venturini M, Tibaldi C, Bengala C, Gallo L, Carnino F, et al. Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. Breast Cancer Res Treat. 2000;59(2):133-9.
6. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440-9.
7. Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol. 2012;30(9):921-9.
8. Katsumata N, Watanabe T, Minami H, Aogi K, Tabei T, Sano M, et al. Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802). Ann Oncol. 2009;20(7):1210-5.
9. Belfiglio M, Fanizza C, Tinari N, Ficorella C, Iacobelli S, Natoli C. Consorzio Interuniversitario Nazionale per la B-O: Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. J Cancer Res Clin Oncol. 2012;138(2):221-9.
10. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andre F, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014;23(5):489-502.
11. Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, et al. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2014;32(29):3307-29.
12. Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol. 2001;12(9):1247-54.
13. Kusama M, Nomizu T, Aogi K, Yoshimoto M, Horikoshi N, Tabei T, et al. Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. Breast Cancer. 2010;17(4):233-40.
14. Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol. 2011;29(34):4498-504.
15. O'Shaughnessy JA, Kaufmann M, Siedentopf F, Dalivoust P, Debled M, Robert NJ, et al. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist. 2012;17(4):476-84.
16. Xu YC, Wang HX, Tang L, Ma Y, Zhang FC. A systematic review of vinorelbine for the treatment of breast cancer. Breast J. 2013;19(2):180-8.
17. Martin M, Ruiz A, Munoz M, Balil A, Garcia-Mata J, Calvo L, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007;8(3):219-25.
18. Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 2001;92(9):2267-72.
19. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology. 2002;62(1):2-8.
20. Rha SY, Moon YH, Jeung HC, Kim YT, Sohn JH, Yang WI, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat. 2005;90(3):215-21.
21. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914-23.
22. Thomas E, Tabernero J, Fornier M, Conte P, Fumoleau P, Lluch A, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007;25(23):3399-406.
23. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002;3(6):430-40.
24. Pizzolato JF, Saltz LB. The camptothecins. Lancet. 2003;361(9376):2235-42.
25. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008;26(16):2690-8.
26. Horisberger K, Erben P, Muessle B, Woernle C, Stroebel P, Kaehler G, et al. Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs. 2009;20(6):519-24.
27. Romer MU, Jensen NF, Nielsen SL, Muller S, Nielsen KV, Nielsen HJ, et al. TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity. Scand J Gastroenterol. 2012;47(1):68-79.
28. Nygard SB, Christensen IJ, Nielsen SL, Nielsen HJ, Brunner N, Spindler KL. Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer. Scand J Gastroenterol. 2014;49(1):84-91.
29. Kumler I, Brunner N, Stenvang J, Balslev E, Nielsen DL. A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2013;138(2):347-58.
30. Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 2004;22(14):2849-55.
31. Vukelja S, O'Shaughnessy J, Campos L, Vahdat J, Blum J, Yardley P, et al. Activity of oral irinotecan n metastatic breast cancer patients after prior anthracycline, taxane and capecitabine: phase 2 study results. J Clin Oncol (Meeting Abstracts). 2005;23(16, Suppl):562.
32. Hayashi H, Tsurutani J, Satoh T, Masuda N, Okamoto W, Morinaga R, et al. Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B. Breast Cancer. 2013;20(2):131-6.
33. Shigeoka Y, Itoh K, Igarashi T, Ishizawa K, Saeki T, Fujii H, et al. Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens. Jpn J Clin Oncol. 2001;31(8):370-4.
34. Garcia AA, Awada A, Chan S, Jerusalem G, Coleman RE, Huizing MT, et al.: Final results of NKTR-102, a topoisomeraseI inhibitor-polymer conjugate in patients with pretreated metastatic breast cancer demonstrating significant antitumor activity. J Clin Oncol. 2011;29(suppl 27):abstract 269.
35. Lynch BJ, Bronstein IB, Holden JA. Elevations of DNA topoisomerase I in invasive carcinoma of the breast. Breast J. 2001;7(3):176-80.
36. Smith DH, Christensen IJ, Jensen NF, Markussen B, Romer MU, Nygard SB, et al. Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort. PLoS One. 2013;8(4):e60613.
37. Romero A, Caldes T, Diaz-Rubio E, Martin M. Topoisomerase 2 alpha: a real predictor of anthracycline efficacy? Clin Transl Oncol. 2012;14(3):163-8.
38. Maughan TS, Meade AM, Adams RA, Richman SD, Butler R, Fisher D, et al. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? Br J Cancer. 2014;110(9):2178-86.